MultiTAA T cell therapy / Baylor College of Medicine, Marker Therap - LARVOL DELTA

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov) - P1 | N=44 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting

Enrollment closed • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • ANPEP • CD33 • KIT • WT1

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=12 | Completed | Sponsor: Baylor College of Medicine | Active, not recruiting ➔ Completed

Trial completion • Breast Cancer • Oncology • Solid Tumor

STELLA: Administration of Donor MultiTAA-Specific T Cells for ALL (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Baylor College of Medicine | Active, not recruiting ➔ Completed

Trial completion • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD4 • CD8 • MME

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Feb 2026 ➔ Feb 2027 | Trial primary completion date: Apr 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • ANPEP • CD33 • KIT • WT1

TACTIC - TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer (clinicaltrials.gov) - P2 | N=12 | Active, not recruiting | Sponsor: Baylor College of Medicine | Trial completion date: May 2024 ➔ May 2025

Trial completion date • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Baylor College of Medicine | Trial primary completion date: Apr 2023 ➔ Apr 2024

Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • ANPEP • CD33 • KIT • WT1

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. (PubMed, Ther Adv Med Oncol) - "This was associated with in vivo T-cell expansion, persistence, and antigen spreading. Future directions of this approach may include additional strategies to enhance the therapeutic benefit of multiTAA T cells in patients with BC."

Journal • Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • BIRC5 • CTAG1B • ER • HER-2 • MAGEA4 • PGR • PRAME

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) (clinicaltrials.gov) - P1 | N=44 | Recruiting | Sponsor: Baylor College of Medicine | Trial completion date: Feb 2025 ➔ Feb 2026 | Trial primary completion date: Apr 2022 ➔ Apr 2023

Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • CD33 • KIT • WT1

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL (TCT-ASTCT-CIBMTR 2022) - "The preparation and infusion of donor-derived multiTAA-specific T cells to patients with B- and T-ALL post allogeneic HSCT is feasible, safe and as evidenced by in vivo tumor-directed T cell expansion and antigen spreading, may contribute to disease control. This strategy may represent a promising addition to current immunotherapeutic approaches for prophylaxis for leukemic relapse in HSCT recipients."

Clinical • IO biomarker • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • Inflammation • Leukemia • Oncology • Pediatrics • Septic Shock • T Acute Lymphoblastic Leukemia • Transplantation • BIRC5 • CD4 • CD8 • CTAG1B • IFNG • MAGEA4 • MLANA • PRAME • WT1

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL (clinicaltrials.gov) - P1 | N=36 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting | N=74 ➔ 36 | Trial completion date: May 2027 ➔ Sep 2027 | Trial primary completion date: May 2022 ➔ Sep 2021

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology